Leerink Partnrs Raises Earnings Estimates for Zura Bio

Zura Bio Limited (NASDAQ:ZURA) – Research analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Zura Bio in a note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings per share of ($0.64) for the year, up from their previous estimate of ($0.67). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio’s FY2026 earnings at ($0.57) EPS.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12).

ZURA has been the subject of a number of other reports. Leerink Partners assumed coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price for the company. Piper Sandler reissued an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a research report on Monday, November 18th. Chardan Capital reduced their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $15.80.

Zura Bio Stock Performance

NASDAQ ZURA opened at $2.28 on Friday. Zura Bio has a 1-year low of $2.00 and a 1-year high of $6.35. The business has a 50 day simple moving average of $3.76 and a two-hundred day simple moving average of $3.80.

Hedge Funds Weigh In On Zura Bio

Large investors have recently bought and sold shares of the business. Braidwell LP purchased a new stake in Zura Bio in the third quarter worth $10,040,000. Point72 Asset Management L.P. bought a new stake in Zura Bio during the 2nd quarter valued at about $8,446,000. Great Point Partners LLC boosted its position in Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after buying an additional 1,884,501 shares during the period. Armistice Capital LLC grew its stake in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after acquiring an additional 876,000 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of Zura Bio during the third quarter worth approximately $2,999,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Insider Buying and Selling

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 22.10% of the stock is currently owned by corporate insiders.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.